MET and non-small cell lung carcinoma: Other inhibitors of human epidermal growth factor receptor 2 (HER2), ‘rearranged during transfection’ proto-oncogene (RET), and tyrosine-protein kinase Met (MET) have also been approved for the treatment of NSCLC [9,10,11].